The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: Is 'the more the merrier'?

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Martin, F ^a   Taylor, G P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

HAART; Pre term delivery; Vertical transmission

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; MITOCHONDRIAL DNA; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CHILD DEATH; COHORT ANALYSIS; CONGENITAL MALFORMATION; DANDY WALKER SYNDROME; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOSPADIAS; INFECTION PREVENTION; LACTIC ACIDOSIS; MATERNAL WELFARE; MEDICAL DECISION MAKING; PATIENT SELECTION; PRACTICE GUIDELINE; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRESCRIPTION; RISK ASSESSMENT; SMALL FOR DATE INFANT; SPINA BIFIDA; STILLBIRTH; TERATOGENICITY; TREATMENT DURATION; VERTICAL TRANSMISSION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; FETUS; METHODOLOGY; NEWBORN; PREGNANCY COMPLICATION; PREMATURITY; REVIEW;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FETUS; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH;

EID: 73949121009     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp303     Document Type: Article

References (38)

1. Townsend CL, Cortina-Borja M, Peckham CS et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22: 973-81.
2. Antiretroviral Pregnancy Registry Steering Committee. The Antiretroviral Pregnancy Registry: International Interim Report 1 January 1989 through 31 July 2008. Wilmington, NC: Registry Coordinating Center, 2008. http://www.apregistry.com/who.htm.
3. Watts DH, Li D, Handelsman E et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 2007; 44: 299-305.
4. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002; 78: 58-9.
5. Blanche S, Mandelbrot L, Rustin P et al. Persistant mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9.
6. Poirier MC, Divi RL, Al-Harthi L et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33: 175-83.
7. Money D, Maan E, Chaworth-Musters T et al. Mitochondrial DNA levels in pregnancy are not decreased in ARV-treated women compared to HIV2 controls. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 951. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=18 (24 June 2009, date last accessed).
8. Cote HC, Raboud J, Bitnun A et al. Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants. J Infect Dis 2008; 198: 851-9.
9. Brogly S, Foca M, Deville J et al. Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 952. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=18 (24 June 2009, date last accessed).
10. Lorenzi P, Spicher VM, Laubereau B et al. Antiretroviral therapies in pregnancy: maternal, foetal and neonatal effects. AIDS 1998; 12: F241-7.
11. European Collaborative Study, Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-30.
12. Thorne C, Patel D, Newell M-L et al. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18: 2337-9.
13. Townsend CL, Cortina-Borja M, Peckham CS et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 1019-26.
14. Chiesa E, Repetto D, Melzi S et al. Increasing risk of preterm delivery with more potent antiretroviral therapy (ART). In: Abstracts of the Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, 2002. Abstract P322. The Gardiner-Caldwell Group Ltd, Tytherington, Cheshire, UK.
15. Boer K, Nellen JF, Patel D et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. Br J Obstet Gynaecol 2007; 114: 148-55.
16. Grosch-Woerner I, Puch K, Maier RF et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med 2008; 9: 6-13.
17. Kourtis AP, Schmid CH, Jamieson DJ et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21: 607-15.
18. Martin F, Taylor GP. Increased rates of preterm delivery are associated with the initiation of highly active antiretrovial therapy during pregnancy: a single-center cohort study. J Infect Dis 2007; 196: 558-61.
19. Townsend C, Cortina-Borja M, Tookey P. Premature delivery and mother-to-child HIV transmission: risk:benefit analysis of HAART in pregnancy. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 927. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=18 (24 June 2009, date last accessed).
20. Ravizza M, Martinelli P, Bucceri A et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis 2007; 195: 913-4.
21. Schulte J, Dominguez K, Sukalac T et al. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004. Pediatrics 2007; 119: e900-6.
22. Tuomala RE, Shapiro DE, Mofenson LM et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346: 1863-70.
23. Tuomala RE, Watts DH, Li D et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38: 449-73.
24. Cotter AM, Garcia AG, Duthely ML et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193: 1195-201.
25. Szyld EG, Warley EM, Freimanis L et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006; 20: 2345-53.
26. Machado ES, Hofer CB, Costa TT et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85: 82-7.
27. Stratton P, Tuomala RE, Abboud R et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 179-86.
28. Wimalasundera RC, Larbalestier N, Smith JH et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360: 1152-4.
29. Suy A, Martinez E, Coll O et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20: 59-66.
30. Phanupak N, Apornpong T, Limpongsanurak S et al. Pregnancy outcomes of women receiving efavirenz after the first trimester. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 641. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=18 (24 June 2009, date last accessed).
31. Ekouevi D, Tonwe-Gold B, Becquet R et al. Low birth weight with nevirapine-based ART in Abidjan, Cote d'Ivoire: the ANRS Ditrame Plus Cohort and MTCT-Plus Initiative, 2001 to 2007. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 745. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=18 (24 June 2009, date last accessed).
32. Chen J, Ribaudo H, Ogwu A et al. Risk factors for adverse pregnancy outcomes among HIV-infected women in Gaborone, Botswana. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 949. Foundation for Retrovirology and Human Health, Alexandria, VA, USA. http://www.retroconference.org/AbstractSearch/Default.aspx?Conf=18 (24 June 2009, date last accessed).
33. Lallemant M, Jourdain G, Le Coeur S et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217-28.
34. Katzenstein T, Gerstoft J. Zidovudine monotherapy in pregnancy: is it state of the art? HIV Med 2008; 9: 445-7.
35. Taylor GP, O'Shea S, Mercey D et al. Zidovudine monotherapy in pregnancy: is it state of the art? HIV Med 2009; 10: 129-30.
36. de Ruiter A, Mercey D, Anderson J et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9: 452-502.
37. El-Sadr WM, Grund B, Neuhaus J et al. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med 2008; 149: 289-99.
38. Lyall E, Blott M, de Ruiter A et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. British HIV Association. HIV Med 2001; 2: 314 34.